Liothyronine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Liothyronine: From Thyroid Hormone Replacement to Renal Hypodysplasia/Aplasia
One-Sentence Summary
Liothyronine is a synthetic form of the thyroid hormone triiodothyronine (T3), marketed in the US as oral tablets. The TxGNN model predicts it may be effective for renal hypodysplasia/aplasia, but 0 clinical trials and 0 publications support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the US label data provided (liothyronine is a thyroid hormone) |
| Predicted New Indication | Renal hypodysplasia/aplasia |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Liothyronine is a direct thyroid hormone receptor agonist. Thyroid hormone plays a general role in kidney development, which is probably why the knowledge graph links it to this condition.
The link is weak, though. Renal hypodysplasia/aplasia is a structural congenital anomaly, meaning the kidney fails to form properly. No evidence supports postnatal liothyronine treatment for such a condition, and a drug given after birth is unlikely to reverse a structural defect. The high score is more likely a knowledge-graph artifact from shared developmental gene or phenotype associations than a real therapeutic signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA091382 | liothyronine sodium (Sun Pharmaceutical Industries) | Tablet | Not listed in source data |
| ANDA214803 | Liothyronine sodium (A-S Medication Solutions) | Tablet | Not listed in source data |
| ANDA200295 | Liomny (Sigmapharm Laboratories) | Tablet | Not listed in source data |
| ANDA211510 | Liothyronine Sodium (Teva Pharmaceuticals USA) | Tablet | Not listed in source data |
| ANDA090097 | Liothyronine Sodium (Golden State Medical Supply) | Tablet | Not listed in source data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no supporting trials or literature. A pharmacological benefit for a structural congenital kidney anomaly is also biologically implausible. It should not advance beyond the model-prediction stage.
Among the other top-ranked predictions for liothyronine, only nodular goiter has a plausible, though indirect, mechanistic rationale (TSH suppression). It is a better candidate for further review.
To proceed, the following is needed:
- Mechanism of action data (MOA) from DrugBank
- Package insert warnings and contraindications from the FDA label
- Any preclinical or clinical evidence that thyroid hormone affects the pathology of renal hypodysplasia/aplasia
- Approved indication text for the US licenses, to confirm the original indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.